Elevations in NLR at the first year of pirfenidone treatment may be associated with worse prognosis in patients with idiopathic pulmonary fibrosis

The Egyptian Journal of Bronchology

Table 3 Changes in NLR and PLR levels at first year of antifibrotic therapy in patients according to antifibrotic medication

	NLR levels at diagnosis	NLR levels at 1st year	p-values	PLR levels at diagnosis	PLR levels at first year	p-values
Nintedanib	2.3 (1.62)	2.26 (1.46)	0.97	123.2 (68.7)	123.6 (58.5)	0.16
Pirfenidone	2.33 (1.66)	2.78 (1.66)	0.004	111.3 (66.9)	130.9 (78.8)	0.007

Data are presented as median (interquartile range), NLR neutrophil-to-lymphocyte ratio, PLR platelet-to-lymphocyte ratio